



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

164
RECEIVED
APR 15 2002
TECH CENTER 1600/2900

Applicant: De Robertis et al. Examiner: Unknown
Serial No.: 09/903,323 Group Art Unit: 1647
Filed: July 11, 2001 Docket: 510015-261
Due Date: N/A
Title: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - OLIGONUCLEOTIDES
FOR EXPRESS HUMAN FRAZZLED (FRZB-1) PROTEIN

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Commissioner for Patents, Washington, D.C. 20231 on March 29, 2002.

Kelly Walsh
Kelly Walsh

Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement
- ☒ PTO Form 1449
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, 38th Floor
Los Angeles, CA 90067-3024
(310) 788-5000

By: *Spyros J. Lazaris*
Name: Spyros J. Lazaris
Reg. No.: 45,981
SJL/kw



09/903,323

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	De Robertis, et al.	Examiner:	Unknown
Serial No.	09/903,323	Group Art Unit:	1647
Filed:	July 11, 2001	Docket No.	510015-261
Title:	ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – OLIGONUCLEOTIDES FOR EXPRESSING HUMAN FRAZZLED (FRZB-1) PROTEIN		

#7
HQS
12/17/02

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Commissioner for Patents, Washington, D.C. 20231 on March 29, 2002.

Kelly Walsh
Kelly Walsh

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the issuance of an office action in the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(d)(1) and (2) copies of each document cited in the IDS is not submitted. Rather, the Applicant cites to all references submitted or cited in application numbers: 08/878,474 & 09/552,988 and for the Examiner's review.

S/N 09/903,323

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 16-2230.

Respectfully submitted,

Date: MARCH 29, 2002

Spyros J. Lazaris
Spyros J. Lazaris,
Reg. No. 45,981

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5000
FAX: (310) 788-5100